Compare Abeona Therapeutics Inc (ABEO) vs Innodata Inc (INOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Innodata Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Innodata Inc trades at $68.01 (market cap $2.28B). The key difference: Innodata Inc is far larger — about 6.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | INOD | |
|---|---|---|
Market Cap | $373.32M | $2.28B |
Sector | Health | Technology |
52-Week High | $7.23 | $121.50 |
52-Week Low | $4.17 | $34.45 |
Enterprise Value | $228.22M | $2.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Innodata (INOD) trades at $73.12, up 6.16% today but down 33% over the past month after a strong AI-driven rally earlier this year. The stock shows bearish technical signals with support at $69 and resistance at $76. Fundamentally, the company reported strong Q1 2026 earnings with EPS of $0.42 beating expectations of $0.13, driven by 47% margins and AI data services growth. Revenue reached $90.1M in Q1 2026 (Zacks Investment Research, 2026-06-03).
Outlook remains positive with 60% analyst buy ratings and a $130 consensus price target, but risks include high valuation (P/E 65.29), insider selling, and dependence on AI sector momentum. The recent CFO appointment (Accesswire, 2026-06-17) supports growth execution, yet volatility near multi-month highs requires caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
